ATE518859T1 - Neue fluorenderivate, zusammensetzung mit diesen derivaten und verwendung - Google Patents

Neue fluorenderivate, zusammensetzung mit diesen derivaten und verwendung

Info

Publication number
ATE518859T1
ATE518859T1 AT06755509T AT06755509T ATE518859T1 AT E518859 T1 ATE518859 T1 AT E518859T1 AT 06755509 T AT06755509 T AT 06755509T AT 06755509 T AT06755509 T AT 06755509T AT E518859 T1 ATE518859 T1 AT E518859T1
Authority
AT
Austria
Prior art keywords
derivatives
composition
new fluorene
new
fluorene derivatives
Prior art date
Application number
AT06755509T
Other languages
English (en)
Inventor
Patrick Mailliet
Luc Bertin
Thierry Guyon
Fabienne Thompson
Jean-Marie Ruxer
Fabienne Pilorge
Didier Benard
Herve Minoux
Chantal Carrez
Helene Goulaouic
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE518859T1 publication Critical patent/ATE518859T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06755509T 2005-05-19 2006-05-19 Neue fluorenderivate, zusammensetzung mit diesen derivaten und verwendung ATE518859T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0505037A FR2885904B1 (fr) 2005-05-19 2005-05-19 Nouveaux derives du fluorene, compositions les contenant et utilisation
PCT/FR2006/001137 WO2006123061A2 (fr) 2005-05-19 2006-05-19 Derives du fluorene, compositions les contenant et utilisation

Publications (1)

Publication Number Publication Date
ATE518859T1 true ATE518859T1 (de) 2011-08-15

Family

ID=36036699

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06755509T ATE518859T1 (de) 2005-05-19 2006-05-19 Neue fluorenderivate, zusammensetzung mit diesen derivaten und verwendung

Country Status (31)

Country Link
US (1) US7674795B2 (de)
EP (1) EP1888579B1 (de)
JP (1) JP4964874B2 (de)
KR (1) KR101288696B1 (de)
CN (1) CN101203518B (de)
AR (1) AR054125A1 (de)
AT (1) ATE518859T1 (de)
AU (1) AU2006248825B2 (de)
BR (1) BRPI0611424A2 (de)
CA (1) CA2608378C (de)
CR (1) CR9515A (de)
DO (1) DOP2006000112A (de)
EA (1) EA019027B1 (de)
FR (1) FR2885904B1 (de)
GT (1) GT200600206A (de)
HN (1) HN2006018410A (de)
IL (1) IL187163A (de)
JO (1) JO2753B1 (de)
MA (1) MA29493B1 (de)
MX (1) MX2007014443A (de)
MY (1) MY149037A (de)
NO (1) NO20076460L (de)
NZ (1) NZ563239A (de)
PA (1) PA8675701A1 (de)
PE (1) PE20061367A1 (de)
TN (1) TNSN07389A1 (de)
TW (1) TWI386406B (de)
UA (1) UA93203C2 (de)
UY (1) UY29549A1 (de)
WO (1) WO2006123061A2 (de)
ZA (1) ZA200709856B (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007109160A2 (en) 2006-03-16 2007-09-27 Renovis, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
FR2907453B1 (fr) 2006-10-24 2008-12-26 Sanofi Aventis Sa Nouveaux derives du fluorene,compositions les contenant et utilisation
KR20100106414A (ko) * 2007-11-22 2010-10-01 이데미쓰 고산 가부시키가이샤 유기 ｅｌ 소자
EP2276733A2 (de) * 2008-03-31 2011-01-26 Council Of Scientific & Industrial Research Neue donor-akzeptor-fluorengerüste: ein verfahren und anwendungen davon
GB0809314D0 (en) * 2008-05-22 2008-07-02 Summit Corp Plc Compounds for treating muscular dystrophy
WO2009158118A2 (en) 2008-05-30 2009-12-30 University Of Notre Dame Du Lac Anti-bacterial agents from benzo[d]heterocyclic scaffolds for prevention and treatment of multidrug resistant bacteria
FR2932484B1 (fr) 2008-06-16 2010-06-18 Sanofi Aventis Nouveaux derives de pyrroloindole inhibiteurs d'hsp90, compositions les contenant et utilisation
NZ589759A (en) * 2008-07-02 2012-12-21 British Columbia Cancer Agency Diglycidic ether derivative therapeutics and methods for their use
AR074797A1 (es) 2008-10-10 2011-02-16 Japan Tobacco Inc Compuesto de fluoreno , composiciones farmaceuticas , inhibidores de pdhk y pdhk2 , metodos de tratamiento , usos de los mismos y kit comercial
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
AR079846A1 (es) 2010-01-06 2012-02-22 British Columbia Cancer Agency Agentes terapeuticos derivados de bisfenol que contienen un grupo aquiral y su uso en el tratamiento del cancer
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
WO2012145330A1 (en) * 2011-04-18 2012-10-26 The University Of British Columbia Fluorene-9-bisphenol compounds and methods for their use
CN102442973A (zh) * 2011-09-22 2012-05-09 华东理工大学 催化氧化伯醇闭环合成苯并咪唑和苯并噻唑化合物的方法
US9761820B2 (en) 2012-01-31 2017-09-12 Cambridge Display Technology Limited Polymer
US9365510B2 (en) 2012-04-16 2016-06-14 British Columbia Cancer Agency Branch Aziridine bisphenol ethers and related compounds and methods for their use
AU2013266086B2 (en) 2012-05-25 2018-03-01 Berg Llc Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta
WO2014142290A1 (ja) 2013-03-15 2014-09-18 日本たばこ産業株式会社 ピラゾール－アミド化合物およびその医薬用途
EP2994451A4 (de) 2013-05-10 2016-10-05 British Columbia Cancer Agency Esterderivate von androgenrezeptormodulatoren und verfahren zu deren verwendung
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
US9375496B2 (en) 2013-09-09 2016-06-28 British Columbia Cancer Agency Branch Halogenated compounds for cancer imaging and treatment and methods for their use
KR102280686B1 (ko) 2014-02-11 2021-07-22 삼성전자주식회사 카바졸계 화합물 및 이를 포함한 유기 발광 소자
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
JP6778114B2 (ja) * 2014-04-14 2020-10-28 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． イミド系タンパク質分解モジュレーター及び関連する使用方法
WO2015188198A2 (en) 2014-06-06 2015-12-10 Berg Llc Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta
US11426386B2 (en) 2014-12-05 2022-08-30 Case Western Reserve University Compositions and methods of modulating S-nitrosylation
US12551467B2 (en) 2014-12-05 2026-02-17 Case Western Reserve University Compositions and methods of modulating S-nitrosylation
CA3254372A1 (en) 2014-12-05 2025-06-28 Case Western Reserve University Compositions and methods of modulating s-nitrosylation
JP6884100B2 (ja) 2015-01-13 2021-06-09 ブリティッシュ コロンビア キャンサー エージェンシー ブランチ がんの画像化及び治療用のヘテロ環式化合物ならびにそれらの使用方法
US10471023B2 (en) 2015-03-12 2019-11-12 British Columbia Cancer Agency Branch Bisphenol ether derivatives and methods for using the same
CA2988414C (en) * 2015-06-04 2023-09-26 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
US20170298033A1 (en) 2016-04-15 2017-10-19 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
CN114716377A (zh) 2016-07-29 2022-07-08 日本烟草产业株式会社 吡唑-酰胺化合物的制造方法
US11576900B2 (en) 2017-09-25 2023-02-14 Case Western Reserve University Compositions and methods of reducing serum cholesterol and PCSK9
WO2019226991A1 (en) 2018-05-25 2019-11-28 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
US11931339B2 (en) 2018-06-25 2024-03-19 Case Western Reserve University Compositions and methods for treating tissue injury
WO2020061566A1 (en) * 2018-09-21 2020-03-26 Case Western Reserve University Aldoketo reductase inhibitors and uses thereof
KR20210093886A (ko) 2018-10-18 2021-07-28 에싸 파마 아이엔씨. 안드로겐 수용체 조절제 및 그 사용 방법
CN109574917B (zh) * 2018-12-03 2020-12-08 武汉尚赛光电科技有限公司 一种芴酮衍生物及其制备和应用
EP3906029A4 (de) 2018-12-31 2022-09-21 Biomea Fusion, LLC Inhibitoren der menin-mll-interaktion
EA202191852A1 (ru) 2018-12-31 2022-03-18 Биомеа Фьюжн, Ллс Необратимые ингибиторы взаимодействия менин-mll
US12109179B2 (en) 2019-03-28 2024-10-08 Essa Pharma Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
US12391703B2 (en) 2019-09-23 2025-08-19 Case Western Reserve University Aldoketo reductase inhibitors and uses thereof
CN110981795B (zh) * 2019-12-18 2021-02-12 武汉世纪久海检测技术有限公司 一种利用2-氰基异烟酸甲酯制备2-氨酰基异烟酸的方法
JP2023522040A (ja) 2020-04-17 2023-05-26 エッサ ファーマ，インコーポレイテッド Ｎ末端ドメインアンドロゲン受容体阻害剤の固体形態およびその使用
MX2023010941A (es) * 2021-03-17 2023-11-28 Janssen Sciences Ireland Unlimited Co Compuestos antibacterianos.
AU2022325861A1 (en) 2021-08-11 2024-02-29 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
IL310717A (en) 2021-08-20 2024-04-01 Biomea Fusion Inc Crystalline form of N-[4-[4-(4-morpholinyl)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO ] -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, IRREVERSIBLE MENIN-MLL INHIBITOR FOR CANCER TREATMENT
TW202430528A (zh) 2023-01-18 2024-08-01 美商拜歐米富士恩股份有限公司 Ｎ－［４－［４－（４－嗎啉基）－７ｈ－吡咯並［２，３－ｄ］嘧啶－６－基］苯基］－４－［［３（ｒ）－［（１－氧代－２－丙烯－１－基）氨基］－１－哌啶基］甲基］－２－吡啶甲醯胺的結晶形式作為ｍｅｎｉｎ－ｍｌｌ相互作用的共價抑制劑

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997000257A1 (en) * 1995-06-14 1997-01-03 Yamanouchi Pharmaceutical Co., Ltd. Fused imidazole derivatives and medicinal composition thereof
RU2317988C2 (ru) * 2000-08-14 2008-02-27 Орто-Макнейл Фармасьютикал, Инк. Замещенные пиразолы, фармацевтическая композиция на их основе, применение фармацевтической композиции и способ ингибирования активности катепсина s
JP4399265B2 (ja) * 2001-12-21 2010-01-13 ヴァーナリス（ケンブリッジ）リミテッド ３，４−ジアリールピラゾール、および癌の治療におけるそれらの使用
GB0228417D0 (en) 2002-12-05 2003-01-08 Cancer Rec Tech Ltd Pyrazole compounds
GB0229618D0 (en) 2002-12-19 2003-01-22 Cancer Rec Tech Ltd Pyrazole compounds
WO2004058176A2 (en) * 2002-12-20 2004-07-15 Pharmacia Corporation Acyclic pyrazole compounds
US7160885B2 (en) * 2003-02-10 2007-01-09 Cgi Pharmaceuticals, Inc. Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity
CA2515726C (en) 2003-02-11 2012-07-10 Vernalis (Cambridge) Limited Isoxazole compounds
GB0309637D0 (en) 2003-04-28 2003-06-04 Cancer Rec Tech Ltd Pyrazole compounds
CA2530374C (en) * 2003-06-27 2012-05-15 Kyowa Hakko Kogyo Co., Ltd. Hsp90 family protein inhibitors
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
WO2005021552A1 (en) 2003-08-29 2005-03-10 Vernalis (Cambridge) Ltd Pyrimidothiophene compounds
GB0323810D0 (en) * 2003-10-10 2003-11-12 Cancer Rec Tech Ltd Pyridothiophene compounds
EP1704856A4 (de) * 2003-12-26 2009-08-19 Kyowa Hakko Kirin Co Ltd Proteininhibitor der hsp90-familie
FR2884252B1 (fr) * 2005-04-08 2007-05-18 Aventis Pharma Sa Nouveaux derives d'isoindoles, compositions les contenant, leur preparation et leurs utilisations pharmaceutiques notamment en tant qu'inhibiteurs d'activites de la proteine chaperone hsp90

Also Published As

Publication number Publication date
AU2006248825B2 (en) 2012-02-23
AR054125A1 (es) 2007-06-06
FR2885904A1 (fr) 2006-11-24
TW200716633A (en) 2007-05-01
WO2006123061A3 (fr) 2007-01-11
CN101203518B (zh) 2013-07-24
EA019027B1 (ru) 2013-12-30
CA2608378A1 (fr) 2006-11-23
KR20080025375A (ko) 2008-03-20
NZ563239A (en) 2011-01-28
TNSN07389A1 (en) 2009-03-17
UA93203C2 (ru) 2011-01-25
US20080153837A1 (en) 2008-06-26
GT200600206A (es) 2006-12-26
JO2753B1 (en) 2014-03-15
NO20076460L (no) 2008-02-19
KR101288696B1 (ko) 2013-07-22
PA8675701A1 (es) 2006-12-07
HN2006018410A (es) 2010-03-05
FR2885904B1 (fr) 2007-07-06
TWI386406B (zh) 2013-02-21
IL187163A (en) 2014-07-31
MX2007014443A (es) 2008-02-11
EP1888579A2 (de) 2008-02-20
PE20061367A1 (es) 2007-01-08
ZA200709856B (en) 2009-12-30
CR9515A (es) 2008-02-21
BRPI0611424A2 (pt) 2010-09-08
MY149037A (en) 2013-07-15
UY29549A1 (es) 2006-12-29
AU2006248825A1 (en) 2006-11-23
WO2006123061A2 (fr) 2006-11-23
JP2008540620A (ja) 2008-11-20
JP4964874B2 (ja) 2012-07-04
EP1888579B1 (de) 2011-08-03
CN101203518A (zh) 2008-06-18
CA2608378C (fr) 2013-12-31
US7674795B2 (en) 2010-03-09
IL187163A0 (en) 2008-02-09
DOP2006000112A (es) 2007-01-31
MA29493B1 (fr) 2008-05-02
EA200702531A1 (ru) 2008-04-28

Similar Documents

Publication Publication Date Title
ATE518859T1 (de) Neue fluorenderivate, zusammensetzung mit diesen derivaten und verwendung
ATE533481T1 (de) Formulierung mit metformin und vildagliptin
ATE485941T1 (de) Werkstoffverbund mit explosionsgeschweisstem zwischenstück
DE602006017429D1 (de) Saugfähige artikel mit wärmekunststoffbeschichteten supersaugfähigen polymermaterialien
ATE543808T1 (de) 5,6-ring-annelierte indolderivate und ihre verwendung
DE602006000525D1 (de) Mehrbandvorverzerrer mit Korrekturwertetabellen
IL225206A (en) A derivative of multinuclear carbamoylpyridone, its pharmaceutical composition and its use
IL190754A0 (en) Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof
DE602006014125D1 (de) Banksitz mit beweglichen polstern
DE602005011683D1 (de) Turbolader mit variabler düse
DE602005022910D1 (de) Azo-verbindung, tintenzusammensetzung und färbematerial
DE602005021959D1 (de) Substituierte diazaspiroä4.5üdecanderivate und der
EP1887891A4 (de) Ballaststoffzusammensetzung mit glucomannan, xanthangummi und alginat
DE602005012822D1 (de) Nmr-hf-spulen mit aufgeteilten beweglichen kapazitätsbändern
DE602007007692D1 (de) Tintenzusammensetzung und Tintenpatrone mit der Tintenzusammensetzung
DE602006006428D1 (de) Material mit trennbarer struktur
DE602005025604D1 (de) Schalter und einrichtung mit dem schalter
NL1031627A1 (nl) Acylaminobicyclische heteroaromatische verbindingen en toepassingen daarvan.
EP1854446A4 (de) Antiallergische zusammensetzung
ATE542806T1 (de) Diarylmethylpiperazinderivate, deren herstellung und deren verwendung
DE602005020457D1 (de) Master-slave-flip-flop, trigger-flip-flop und zähler
DE502006006105D1 (de) Matrize mit kleinen näpfchenartigen vertiefungen
DE602006018391D1 (de) Photoresistmonomer, dessen Polymer und diesen enthaltende Fotolackzusammensetzung
ATE445604T1 (de) Neue 2,6-diaminopyridin-3-on-derivate
DE602005009139D1 (de) Router mit speziellen Funktionen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties